Factors predicting medicare national coverage: An empirical analysis

Medical Care

Volumn 50, Issue 3, 2012, Pages 249-256

  Chambers, James D ^a,b   Morris, Stephen ^c   Neumann, Peter J ^b   Buxton, Martin J ^a  

^a BRUNEL UNIVERSITY   (United Kingdom)

^b TUFTS MEDICAL CENTER   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

cost effectiveness; Medicare; Medicare coverage

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DECISION MAKING; HEALTH INSURANCE; HEALTH SERVICE; LOGISTIC REGRESSION ANALYSIS; MEDICARE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; QUALITY CONTROL; RESOURCE ALLOCATION; UNITED STATES;

COST-BENEFIT ANALYSIS; ELIGIBILITY DETERMINATION; HUMANS; INSURANCE COVERAGE; MEDICARE; UNITED STATES;

EID: 84857641589     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0b013e318241eb40     Document Type: Article

References (37)

1. National Health Expenditures 2009 Highlights. Baltimore, MD: Centers for Medicare and Medicaid Services. www.cms.gov/NationalHealth ExpendData/downloads/ highlights.pdf.
2. Congressional Budget Office, Economic and Budget Outlook Fiscal Years 2008-2017. Available at http://www.cbo.gov/doc.cfm?index=7731. Accessed 15 March 2010.
3. Notice: Medicare Program; "Revised Process for Making Medicare National Coverage Determinations," Federal Register 68, no. 187(26 September 2003); and GAO, Medicare: Divided Authority.
4. Tufts Medical Center Medicare NCD Database [Database]. Boston, MA: Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center. Updated June 14, 2011.
5. Centers for Medicare and Medicaid Services (CMS). National Coverage Determinations (NCDs). Available at http://www.cms.hhs.gov/mcd/index-list.asp? list-type=ncd. Accessed 15 March 2010.
6. Centers for Medicare and Medicaid Services (CMS). Medicare Coverage Determination Process. Available at http://www.cms.hhs.gov/DeterminationProcess/ . Accessed 15 March 2010.
7. Foote SB. Why Medicare cannot promulgate a national coverage rule: a case of regular mortis. J Health Polit Policy Law. 2002;27:707-730.
8. Kolber MS. Opacity and cost effectiveness analysis in Medicare coverage decisions: health policy encounters administrative law. Food Drug Law J. 2009;64:515-530.
9. Neumann PJ. Resistance to CEA in the United States. In: Neumann PJ, ed. Using Cost-effectiveness Analysis to Improve Health Care-Opportunities and Barriers. Oxford University Press: New York; 2005:19-27.
10. Guidance for the Public, Industry and CMS Staff. Factors CMS Considers in Opening a National Coverage Determination Document Issued: April 11, 2006. Available at https://www.cms.gov/medicarecoveragedatabase/details/medicare- coverage-document-details.aspx? MCDId=6&McdName= Factors+CMS+Considers+in+Opening+a+ National+Coverage+Determination& mcdtypename=Guidance+Documents &MCDIndexType=1&bc=BAAIAAAAAAAA&. Accessed 15 March 2010.
11. Tunis SR, Pearson SD. Coverage options for promising technologies: Medicare's 'coverage with evidence development'. Health Aff (Millwood). 2006;25:1218-1230.
12. Hutton J, Trueman P, Henshall C. Coverage with evidence development: an examination of conceptual and policy issues. Int J Technol Assess Health Care. 2007;23:425-432.
13. Mohr PE, Tunis SR. Access with evidence development: the US experience. Pharmacoeconomics. 2010;28:153-162.
14. Chambers JD, Neumann PJ, Buxton MJ. Does Medicare have an implicit cost-effectiveness threshold? Med Decis Making. 2010;30:E14-27.
15. Dranove D, Hughes EF, Shanley M. Determinants of HMO formulary adoption decisions. Health Serv Res. 2003;38(1 pt 1):169-190.
16. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 2004;13:437-452.
17. Dakin HA, Devlin NJ, Odeyemi IA. "Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making. Health Policy. 2006;77:352-367.
18. Harris AH, Hill SR, Chin G, et al. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004. Med Decis Making. 2008;28:713-722.
19. Chim L, Kelly PJ, Salkeld G, et al. Are cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia? Pharmacoeconomics. 2010;28:463-475.
20. Centers for Medicare and Medicaid Services: Medicare Coverage Center. Available at http://www.cms.hhs.gov/center/coverage.asp. Accessed 15 March 2010.
21. U. S. Preventive Services Task Force Grade Definitions Prior to May 2007. May 2008. Available http://www.uspreventiveservicestaskforce.org/uspstf/ gradespre.htm Accessed14 June 2011.
22. Centers for Medicare and Medicaid Services. Abarelix for the Treatment of Prostate Cancer (CAG-00238N). Available http://www.cms.gov/medicare-coverage- database/details/nca-decision-memo.aspx?NCAId=129&ver=35&NcaName= Abarelix+for+the+Treatment+of+Prostate+ Cancer&DocID=CAG-00238N&bc= gAAAAAgAIAAA&. Accessed 14 June 2011.
23. Centers for Medicare and Medicaid Services. Screening Immunoassay Fecal-Occult Blood Test (CAG-00180 N). Available http://www.cms.gov/medicare- coverage-database/details/nca-decision-memo.aspx?NCAId=87&ver= 13&NcaName=Screening+Immunoassay+Fecal-Occult+Blood+Test&DocID= CAG-00180N&bc=gAAAAAgAIAAA&. Accessed 14 June 2011.
24. PubMed, a service of the National Library of Medicine. Available at http://www.ncbi.nlm.nih.gov/pubmed/. Accessed 15 March 2010.
25. Tufts Medical Center CEA Registry. Available at www.tufts-nemc.org/ cearegistry/. Accessed 15 March 2010.
26. Health Economic Evaluations Database. Available at http://online library.wiley.com/book/10.1002/9780470510933. Accessed 14 June 2011.
27. NHS Economic Evaluation Database. Available at http://www.crd.york. ac.uk/crdweb/. Accessed 15 March 2010.
28. Organisation for Economic Co-operation and Development. Purchasing Power Parity. (PPP) Statistics. Available at http://www.oecd.org/data oecd/61/56/39653523.xls. Accessed 15 March 2010.
29. U. S. Department of Labor. Bureau of Labor Statistics. Available at http://data.bls.gov/cgi-bin/cpicalc.pl. Accessed 15 March 2010.
30. Centers for Medicare and Medicaid Services (CMS). National Health Expenditure Data. Table 4. Available at https://www.cms.gov/ NationalHealthExpendData/downloads/tables.pdf. Accessed 14 June 2011.
31. StataCorp [computer program]. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP; 2009.
32. Chambers JD, Neumann PJ. Listening to Provenge-what a costly cancer treatment says about future Medicare policy. N Engl J Med. 2011;364:1687-1689.
33. Garg S, Ahnen DJ. Is computed tomographic colonography being held to a higher standard? Ann Intern Med. 2010;152:178-181.
34. Dhruva SS, Phurrough SE, Salive ME, et al. CMS's landmark decision on CT colonography-examining the relevant data. N Engl J Med. 2009;360:2699-2701.
35. Pearson SD, Bach PB. How Medicare could use comparative effectiveness research in deciding on new coverage and reimbursement. Health Aff (Millwood). 2010;29:1796-1804.
36. Lesser LI, Krist AH, Kamerow DB, et al. Comparison between US Preventive Services Task Force recommendations and Medicare coverage. Ann Fam Med. 2011;9:44-49.
37. Dolan P, Shaw R, Tsuchiya A, et al. QALY maximisation and people's preferences: a methodological review of the literature. Health Econ. 2005;14:197-208.